PCSK9 and familial hypercholesterolemia: Although these differences in the treatment effect can be attributed to the diverse genotype sequence variations and the higher production rate of PCSK9 in patients with HoFH than with heterozygous familial hypercholesterolemia, it is likely that inclisiran requires sufficient residual LDLR function to be effective in patients with HoFH.